Viking Therapeutics, Inc. - Common Stock (VKTX)

Long-time shareholders are already pretty satisfied with these companies, but there might be even more upside ahead.

Demand for weight loss drugs may fuel growth for more than one player.

If you are looking for a GLP-1 investment, you can buy the leader, the underdog, or the upstart.

This dark horse in the weight loss drug race is worth keeping on your watch list.

The company is riding an incredible tailwind.

Eli Lilly is dominating one of the biggest growth markets in healthcare: the weight loss drug market.

BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (“T2DM”) rank among the most urgent and costly healthcare problems facing the world today, contributing to surging rates of cardiovascular disease, fatty liver disease, kidney complications and ballooning healthcare expenses. What once represented a specialized class of diabetes treatments has grown into one of the most consequential therapeutic categories in modern medicine, with GLP-1 receptor agonists now fundamentally restructuring how obesity, metabolic disease and potentially even neurodegeneration are treated. Operating in this environment is SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) ( Profile ), which through its subsidiary GlucaPharm Inc. is developing a distinct next-generation GLP-1 platform built around GEP-44, a novel triple agonist peptide engineered to improve efficacy, tolerability, and delivery flexibility within one of the most commercially dynamic pharmaceutical markets in history. SureNano is one of the emerging microcap companies active in the GLP-1 space, operating alongside established leaders including Merck & Co. Inc. (NYSE: MRK), AbbVie Inc. (NYSE: ABBV), Viking Therapeutics Inc. (NASDAQ: VKTX) and…

This article has been disseminated on behalf of SureNano Science Ltd. and may include paid advertising.

The Street is bullish on this biotech's prospects, but is the sentiment justified?

AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (T2DM) rank among the most urgent and costly healthcare problems facing the world today, contributing to surging rates of cardiovascular disease, fatty liver disease, kidney complications and ballooning healthcare expenses. What once represented a specialized class of diabetes treatments has grown into one of the most consequential therapeutic categories in modern medicine, with GLP-1 receptor agonists now fundamentally restructuring how obesity, metabolic disease and potentially even neurodegeneration are treated. Operating in this environment is SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) (profile), which through its subsidiary GlucaPharm Inc. is developing a distinct next-generation GLP-1 platform built around GEP-44, a novel triple agonist peptide engineered to improve efficacy, tolerability, and delivery flexibility within one of the most commercially dynamic pharmaceutical markets in history. SureNano is one of the emerging microcap companies active in the GLP-1 space, operating alongside established leaders including Merck & Co. Inc. (NYSE: MRK), AbbVie Inc. (NYSE: ABBV), Viking Therapeutics Inc. (NASDAQ: VKTX) and Altimmune Inc. (NASDAQ: ALT).

Lilly's weight loss drugs have been delivering blockbuster revenue.

This particular player has seen its yield rise in recent years.

Most investors currently see the glass on this stock as being half-empty. Analysts, however, still view the glass as at least half-full.

The weight loss drug market may reach almost $100 billion in a few years.

From stem cell therapies for frailty to α-Klotho protein programs and GLP-1 drug classes now labeled "longevity therapeutics," the science and the capital have finally met

One is a behemoth, the other is a minnow, but both have promising opportunities in the GLP-1 space.

The stock could have plenty of room to run from current levels.

The answer to the question might surprise many investors. It pays to be open-minded about risk.

There is a wide range of possibilities.

As of April 2026, the biotech landscape has undergone a seismic shift, moving from the "hype cycle" of early weight-loss treatments into an era of aggressive strategic consolidation. The market for GLP-1 receptor agonists and multi-pathway incretins, once estimated to be a two-horse race, is now the frontline of a

Shares of Eli Lilly and Company (NYSE: LLY) surged 3.8% on Wednesday following the milestone FDA approval of Foundayo (orforglipron), the first once-daily oral weight-loss pill that does not require strict fasting or water intake restrictions. The approval, which came months ahead of initial analyst expectations, marks a pivotal

There are some tempting bargains if you know where to look.

This little-known biotech could have a big hit on its hands with VK2735, a GLP-1 weight loss drug candidate.